Although this MuSK agonist antibody #13 would not alone function as therapy for SMA, a MuSK agonist antibody may complement other therapies for SMA by promoting synapse maintenance and preventing synapse disruption, thereby mitigating further deterioration of NMJ innervation and function, and maximizing therapeutic effectiveness for all types of SMA patients. This evidence concerns the gene MUSK and proximal spinal muscular atrophy.